A Phase 1 interventional study of IRL757 and Placebo in Not Determined, sponsored by Integrative Research Laboratories AB. Completed at 1 site in Sweden. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by Integrative Research Laboratories AB · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 1, First-In-Human study evaluating the safety and tolerability of single and multiple ascending oral doses of IRL757 in healthy volunteers.
The trial is composed of two parts: Single Ascending Dose (SAD) part and Multiple Ascending Dose (MAD) part.
The SAD part of the trial will be a parallel group design with one pre-defined starting dose and up to four tentative ascending dose levels of IRL757. Eligible and consenting participants will be included in one of five cohorts, with 8 participants in each cohort (ratio 1:3 placebo/IRL757).
The MAD part of the trial will start after completion of the SAD part of the trial. Depending on the data from the SAD part, two or three dose levels will be evaluated in the MAD part of the trial. There will be 12 participants in each cohort (ratio 1:3 placebo/IRL757).
At the screening visit, consenting subjects will be screened for eligibility according to study specific inclusion/exclusion criteria within 4 weeks before Investigational Medicinal Product (IMP) administration.
If eligible, participants will be admitted to the phase 1 clinic for allocation and administration of the IMP: single dose in the SAD part of the trial or repeated dose (treatment administered repeatedly for 10 days) in the MAD part of the trial. Participants will receive IRL757 or placebo, as randomized.
The treatment allocation will be double-blind, i.e. it will not be disclosed to the patients, the site staff or the Sponsor.
A follow-up visit will be performed for all participants, 5-10 days after IMP administration.
Safety assessments will be performed throughout the study: review and collection of adverse events, physical examination, suicidality ideation, electrocardiogram recording, vital signs, safety laboratory assessments. Blood and urine sampling will also be performed for determination of pharmacokinetic parameters.
Integrative Research Laboratories AB is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: IRL757
Drug: Placebo
IRL757 capsule
Placebo capsule
Evaluation of Frequency, Seriousness and Intensity of Adverse Events
Total number of AEs, and total number of AEs by severity and relationship to study treatment are presented. Refer to the Adverse Events section for more information
Time frame: Until 5-10 days after IMP administration
Description of Physical Examination Findings
Number of participants with clinically significant abnormal findings on physical examination
Time frame: Until 5-10 days after IMP administration
Description of Electrocardiogram Findings
Number of participants with clinically significant abnormal electrocardiogram findings
Time frame: Until 5-10 days after IMP administration
Description of Vital Signs Findings
Number of participants with clinically significant abnormal vital signs findings
Time frame: Until 5-10 days after IMP administration
Description of Safety Laboratory Measurements
Number of participants with clinically significant abnormal safety laboratory measurements
Time frame: Until 5-10 days after IMP administration
Description of C-SSRS (Columbia Suicide Severity Rating Scale) Findings
Number of Participants With Suicidal Thoughts or Attempts
Time frame: Until 5-10 days after IMP administration
Determination of Maximum Plasma Concentration [Cmax] of IRL757 and Its 3 Main Metabolites
Geometric mean and geometric coefficient of variation (CV%) for maximum plasma concentration. Data from Pharmacokinetic analysis set. All samples from all participants were subject to analysis of IRL757 and main metabolite concentrations.
Time frame: Until 48 hours post-dose
Determination of the AUC of IRL757 and Its 3 Main Metabolites After Single and Multiple Dose
Geometric mean and geometric coefficient of variation (CV%) for area under the plasma concentration-time curve (AUC0-inf for SAD and AUC0-tau for MAD). Data from Pharmacokinetic analysis set. All samples from all participants were subject to analysis of IRL757 and main metabolite concentrations.
Time frame: Until 48 hours post-dose
Determination of the Time for Maximum Concentration [Tmax] of IRL757 and Its 3 Main Metabolites
Median time to maximum plasma concentration with full range (minimum, maximum). Data from Pharmacokinetic analysis set. All samples from all participants were subject to analysis of IRL757 and main metabolite concentrations.
Time frame: Until 48 hours post-dose
Determination of the Half-life [t1/2] of IRL757 and Its 3 Main Metabolites
Geometric mean and geometric coefficient of variation (CV%) for terminal elimination half-life. Data from Pharmacokinetic analysis set. All samples from all participants were subject to analysis of IRL757 and main metabolite concentrations.
Time frame: Until 48 hours post-dose
Determination of the Renal Clearance (CLr) of IRL757
Geometric mean and geometric coefficient of variation (CV%) for renal clearance. Data from Pharmacokinetic analysis set. All samples from all participants were subject to analysis of IRL757 and main metabolite concentrations.
Time frame: Until 48 hours post-dose
| Milestone | SAD Cohort 1 | SAD Cohort 2 | SAD Cohort 3 | SAD Cohort 4 | SAD Cohort 5 | SAD Placebo Cohort | SAD Food Interaction Sub-study | MAD Cohort 1 | MAD Cohort 2 | MAD Cohort 3 | MAD Placebo Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 10 | 6 | 9 | 9 | 9 | 9 |
| Completed | 6 | 6 | 6 | 6 | 6 | 10 | 6 | 9 | 9 | 9 | 9 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total number of AEs, and total number of AEs by severity and relationship to study treatment are presented. Refer to the Adverse Events section for more information
| Adverse events | SAD Cohort 1 | SAD Cohort 2 | SAD Cohort 3 | SAD Cohort 4 | SAD Cohort 5 | SAD Placebo Cohort | SAD Food Interaction Sub-study | MAD Cohort 1 | MAD Cohort 2 | MAD Cohort 3 | MAD Placebo Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Any AE | 7 | 1 | 3 | 4 | 0 | 9 | 9 | 16 | 18 | 9 | 19 |
| Relationship to study treatment - Not Related | 3 | 1 | 2 | 3 | 0 | 2 | 3 | 7 | 11 | 4 | 5 |
| Relationship to study treatment - Possible | 4 | 0 | 1 | 1 | 0 | 6 | 6 | 9 | 7 | 5 | 14 |
| Relationship to study treatment - Probable | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Severity - Mild | 7 | 1 | 3 | 4 | 0 | 9 | 9 | 15 | 18 | 9 | 19 |
| Severity - Moderate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Number of participants with clinically significant abnormal findings on physical examination
| Participants | SAD Cohort 1 | SAD Cohort 2 | SAD Cohort 3 | SAD Cohort 4 | SAD Cohort 5 | SAD Placebo Cohort | SAD Food Interaction Sub-study | MAD Cohort 1 | MAD Cohort 2 | MAD Cohort 3 | MAD Placebo Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Description of Physical Examination Findings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with clinically significant abnormal electrocardiogram findings
| Participants | SAD Cohort 1 | SAD Cohort 2 | SAD Cohort 3 | SAD Cohort 4 | SAD Cohort 5 | SAD Placebo Cohort | SAD Food Interaction Sub-study | MAD Cohort 1 | MAD Cohort 2 | MAD Cohort 3 | MAD Placebo Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Description of Electrocardiogram Findings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with clinically significant abnormal vital signs findings
| Participants | SAD Cohort 1 | SAD Cohort 2 | SAD Cohort 3 | SAD Cohort 4 | SAD Cohort 5 | SAD Placebo Cohort | SAD Food Interaction Sub-study | MAD Cohort 1 | MAD Cohort 2 | MAD Cohort 3 | MAD Placebo Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Description of Vital Signs Findings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with clinically significant abnormal safety laboratory measurements
| Participants | SAD Cohort 1 | SAD Cohort 2 | SAD Cohort 3 | SAD Cohort 4 | SAD Cohort 5 | SAD Placebo Cohort | SAD Food Interaction Sub-study | MAD Cohort 1 | MAD Cohort 2 | MAD Cohort 3 | MAD Placebo Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Description of Safety Laboratory Measurements | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
Number of Participants With Suicidal Thoughts or Attempts
| Participants | SAD Cohort 1 | SAD Cohort 2 | SAD Cohort 3 | SAD Cohort 4 | SAD Cohort 5 | SAD Placebo Cohort | SAD Food Interaction Sub-study | MAD Cohort 1 | MAD Cohort 2 | MAD Cohort 3 | MAD Placebo Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Description of C-SSRS (Columbia Suicide Severity Rating Scale) Findings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Geometric mean and geometric coefficient of variation (CV%) for maximum plasma concentration. Data from Pharmacokinetic analysis set. All samples from all participants were subject to analysis of IRL757 and main metabolite concentrations.
| umol/L | SAD Cohort 1 | SAD Cohort 2 | SAD Cohort 3 | SAD Cohort 4 | SAD Cohort 5 | SAD Food Interaction Sub-study | MAD Cohort 1 | MAD Cohort 2 | MAD Cohort 3 |
|---|---|---|---|---|---|---|---|---|---|
| IRL757 | 2.837 ± 34.5 | 5.884 ± 13.2 | 9.543 ± 10.7 | 24.18 ± 17.7 | 11.26 ± 21.9 | 9.709 ± 9.87 | 2.228 ± 18.7 | 6.002 ± 16.5 | 12.79 ± 15.7 |
| M1 | 0.04644 ± 138 | 0.09647 ± 132 | 0.1563 ± 80.3 | 0.3007 ± 65.5 | 0.1237 ± 78.5 | 0.08305 ± 75.4 | 0.03797 ± 119 | 0.03989 ± 72.4 | 0.2334 ± 126 |
| M5 | 0.09834 ± 12.7 | 0.1841 ± 21.8 | 0.3745 ± 28.8 | 0.6578 ± 20.9 | 0.3811 ± 32.8 | 0.3352 ± 31.1 | 0.1079 ± 19.5 | 0.2045 ± 16.8 | 0.3451 ± 31.2 |
| M7 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| IRL757 Steady state | — | — | — | — | — | — | 5.059 ± 32.6 | 12.24 ± 27.7 | 23.27 ± 35.9 |
| M1 Steady state | — | — | — | — | — | — | 0.06238 ± 103 | 0.1093 ± 54.9 | 0.4950 ± 76.8 |
| M5 Steady state | — | — | — | — | — | — | 0.1079 ± 17.4 | 0.1504 ± 21.8 | 0.2328 ± 52.4 |
| M7 Steady state | — | — | — | — | — | — | NA ± NA | NA ± NA | 0.05658 ± 27.6 |
| IRL757 Fed | — | — | — | — | — | 7.679 ± 16.2 | — | — | — |
| M1 Fed | — | — | — | — | — | 0.06769 ± 85.2 | — | — | — |
| M5 Fed | — | — | — | — | — | 0.1712 ± 24.6 | — | — | — |
| M7 Fed | — | — | — | — | — | NA ± NA | — | — | — |
Geometric mean and geometric coefficient of variation (CV%) for area under the plasma concentration-time curve (AUC0-inf for SAD and AUC0-tau for MAD). Data from Pharmacokinetic analysis set. All samples from all participants were subject to analysis of IRL757 and main metabolite concentrations.
| h*umol/L | SAD Cohort 1 | SAD Cohort 2 | SAD Cohort 3 | SAD Cohort 4 | SAD Cohort 5 | SAD Food Interaction Sub-study | MAD Cohort 1 | MAD Cohort 2 | MAD Cohort 3 |
|---|---|---|---|---|---|---|---|---|---|
| IRL757 | 24.73 ± 58.6 | 56.21 ± 40.1 | 78.06 ± 37.1 | 403.4 ± 41.2 | 134.0 ± 48.2 | 118.8 ± 18.3 | 15.85 ± 18.8 | 37.11 ± 20.2 | 77.13 ± 22.2 |
| M1 | NA ± NA | 1.490 ± 52.1 | 1.642 ± 65.5 | 5.181 ± 67.6 | 1.910 ± 34.6 | 1.291 ± 67.0 | 0.5716 ± 79.2 | 0.3715 ± 67.0 | 1.946 ± 111 |
| M5 | 1.889 ± 36.5 | 3.880 ± 20.3 | 5.942 ± 33.0 | 14.01 ± 24.1 | 7.724 ± 19.3 | 7.379 ± 25.9 | 0.8983 ± 20.3 | 1.734 ± 16.2 | 2.879 ± 32.2 |
| M7 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| IRL757 Steady state | — | — | — | — | — | — | 44.66 ± 41.2 | 105.1 ± 36.6 | 184.0 ± 51.8 |
| M1 Steady state | — | — | — | — | — | — | 0.5687 ± 105 | 1.023 ± 53.1 | 4.260 ± 72.1 |
| M5 Steady state | — | — | — | — | — | — | 1.209 ± 19.7 | 1.674 ± 22.3 | 2.479 ± 48.9 |
| M7 Steady state | — | — | — | — | — | — | NA ± NA | NA ± NA | 0.5515 ± 25.6 |
| IRL757 Fed | — | — | — | — | — | 144.7 ± 13.9 | — | — | — |
| M1 Fed | — | — | — | — | — | 1.652 ± 76.6 | — | — | — |
| M5 Fed | — | — | — | — | — | 4.792 ± 32.2 | — | — | — |
| M7 Fed | — | — | — | — | — | NA ± NA | — | — | — |
Median time to maximum plasma concentration with full range (minimum, maximum). Data from Pharmacokinetic analysis set. All samples from all participants were subject to analysis of IRL757 and main metabolite concentrations.
| hours | SAD Cohort 1 | SAD Cohort 2 | SAD Cohort 3 | SAD Cohort 4 | SAD Cohort 5 | SAD Food Interaction Sub-study | MAD Cohort 1 | MAD Cohort 2 | MAD Cohort 3 |
|---|---|---|---|---|---|---|---|---|---|
| IRL757 | 1.517 (0.667 to 2.08) | 1.508 (0.667 to 3.00) | 1.000 (0.667 to 1.02) | 2.000 (1.03 to 6.00) | 0.8250 (0.667 to 6.00) | 1.033 (1.00 to 2.00) | 1.000 (0.667 to 8.00) | 0.6833 (0.333 to 1.05) | 0.6833 (0.667 to 2.02) |
| M1 | 3.500 (2.00 to 8.00) | 4.000 (2.00 to 6.00) | 3.000 (2.00 to 4.00) | 4.000 (3.00 to 4.02) | 3.500 (1.98 to 4.05) | 3.992 (2.00 to 4.02) | 3.000 (2.98 to 4.00) | 3.000 (1.05 to 4.00) | 3.000 (0.667 to 3.98) |
| M5 | 6.000 (6.00 to 10.0) | 6.000 (5.98 to 8.00) | 8.000 (4.00 to 8.03) | 6.000 (6.00 to 6.10) | 6.000 (6.00 to 8.00) | 6.000 (5.92 to 8.00) | 6.000 (5.93 to 10.1) | 6.000 (6.00 to 7.98) | 6.017 (6.00 to 10.0) |
| M7 | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| IRL757 Steady state | — | — | — | — | — | — | 1.017 (0.667 to 3.02) | 0.9833 (0.667 to 2.02) | 1.000 (0.667 to 6.03) |
| M1 Steady state | — | — | — | — | — | — | 3.000 (1.00 to 4.02) | 2.050 (1.00 to 4.02) | 3.000 (2.00 to 4.00) |
| M5 Steady state | — | — | — | — | — | — | 6.000 (2.00 to 6.07) | 5.983 (1.00 to 6.12) | 4.000 (0.667 to 6.00) |
| M7 Steady state | — | — | — | — | — | — | NA (NA to NA) | NA (NA to NA) | 8.050 (6.00 to 12.0) |
| IRL757 Fed | — | — | — | — | — | 5.983 (3.98 to 8.00) | — | — | — |
| M1 Fed | — | — | — | — | — | 7.033 (5.98 to 10.0) | — | — | — |
| M5 Fed | — | — | — | — | — | 11.00 (8.00 to 12.0) | — | — | — |
| M7 Fed | — | — | — | — | — | NA (NA to NA) | — | — | — |
Geometric mean and geometric coefficient of variation (CV%) for terminal elimination half-life. Data from Pharmacokinetic analysis set. All samples from all participants were subject to analysis of IRL757 and main metabolite concentrations.
| hours | SAD Cohort 1 | SAD Cohort 2 | SAD Cohort 3 | SAD Cohort 4 | SAD Cohort 5 | SAD Food Interaction Sub-study | MAD Cohort 1 | MAD Cohort 2 | MAD Cohort 3 |
|---|---|---|---|---|---|---|---|---|---|
| IRL757 | 6.681 ± 40.0 | 6.813 ± 36.7 | 5.874 ± 33.5 | 11.35 ± 22.3 | 8.969 ± 48.1 | 9.659 ± 8.92 | 6.174 ± 27.5 | 6.193 ± 23.6 | 5.925 ± 33.0 |
| M1 | NA ± NA | 5.202 ± 27.0 | 5.495 ± 47.1 | 10.28 ± 32.3 | 9.538 ± 45.2 | 9.514 ± 22.3 | 7.645 ± 17.6 | 7.111 ± 36.1 | 6.185 ± 66.9 |
| M5 | 10.30 ± 31.9 | 11.69 ± 28.3 | 8.791 ± 21.6 | 13.08 ± 14.4 | 11.47 ± 29.0 | 13.05 ± 15.2 | 15.15 ± 78.6 | 12.35 ± 51.1 | 10.87 ± 32.0 |
| M7 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| IRL757 Steady state | — | — | — | — | — | — | 12.05 ± 19.8 | 11.65 ± 29.9 | 10.50 ± 38.2 |
| M1 Steady state | — | — | — | — | — | — | 10.59 ± 39.8 | 13.03 ± 61.2 | 11.07 ± 43.3 |
| M5 Steady state | — | — | — | — | — | — | 23.95 ± 34.2 | 23.48 ± 30.3 | 20.36 ± 44.6 |
| M7 Steady state | — | — | — | — | — | — | NA ± NA | NA ± NA | 82.96 ± 39.2 |
| IRL757 Fed | — | — | — | — | — | 10.47 ± 9.68 | — | — | — |
| M1 Fed | — | — | — | — | — | 11.84 ± 30.2 | — | — | — |
| M5 Fed | — | — | — | — | — | 15.20 ± 2.06 | — | — | — |
| M7 Fed | — | — | — | — | — | NA ± NA | — | — | — |
Geometric mean and geometric coefficient of variation (CV%) for renal clearance. Data from Pharmacokinetic analysis set. All samples from all participants were subject to analysis of IRL757 and main metabolite concentrations.
| L/h | SAD Cohort 1 | SAD Cohort 2 | SAD Cohort 3 | SAD Cohort 4 | SAD Cohort 5 | MAD Cohort 1 | MAD Cohort 2 | MAD Cohort 3 |
|---|---|---|---|---|---|---|---|---|
| IRL757 Day 1 | 0.09142 ± 83.8 | 0.06989 ± 38.6 | 0.1260 ± 26.7 | 0.09058 ± 64.5 | 0.08338 ± 33.1 | — | — | — |
| IRL757 Steady state | — | — | — | — | — | 0.1141 ± 46.4 | 0.08829 ± 47.0 | 0.08091 ± 42.2 |
Collected over From first IMP administration until follow-up visit 5-10 days after last IMP administration. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SAD Cohort 1 | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| SAD Cohort 2 | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| SAD Cohort 3 | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| SAD Cohort 4 | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| SAD Cohort 5 | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| SAD Placebo Cohort | 0/10 (0%) | 0/10 (0%) | 6/10 (60%) |
| SAD Food Interaction Sub-study | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| MAD Cohort 1 | 0/9 (0%) | 0/9 (0%) | 7/9 (77.8%) |
| MAD Cohort 2 | 0/9 (0%) | 0/9 (0%) | 8/9 (88.9%) |
| MAD Cohort 3 | 0/9 (0%) | 0/9 (0%) | 4/9 (44.4%) |
| MAD Placebo Cohort | 0/9 (0%) | 0/9 (0%) | 8/9 (88.9%) |
| Event | SAD Cohort 1 | SAD Cohort 2 | SAD Cohort 3 | SAD Cohort 4 | SAD Cohort 5 | SAD Placebo Cohort | SAD Food Interaction Sub-study | MAD Cohort 1 | MAD Cohort 2 | MAD Cohort 3 | MAD Placebo Cohort |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 2/6 | 0/6 | 0/6 | 0/6 | 0/6 | 3/10 | 1/6 | 3/9 | 4/9 | 2/9 | 4/9 |
| FatigueGeneral disorders | 2/6 | 0/6 | 1/6 | 0/6 | 0/6 | 1/10 | 0/6 | 0/9 | 1/9 | 0/9 | 0/9 |
| NasopharyngitisInfections and infestations | 0/6 | 0/6 | 1/6 | 1/6 | 0/6 | 0/10 | 1/6 | 0/9 | 2/9 | 1/9 | 3/9 |
| DizzinessNervous system disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 2/10 | 2/6 | 0/9 | 1/9 | 0/9 | 0/9 |
| NauseaGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/10 | 0/6 | 0/9 | 0/9 | 0/9 | 2/9 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 0/6 | 2/9 | 0/9 | 0/9 | 0/9 |
| HyperprolactinaemiaEndocrine disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 2/10 | 0/6 | 0/9 | 0/9 | 0/9 | 0/9 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 1/6 | 1/9 | 0/9 | 0/9 | 0/9 |
| FlatulenceGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 1/6 | 0/9 | 0/9 | 0/9 | 1/9 |
| Medical device site reactionInjury, poisoning and procedural complications | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/10 | 0/6 | 0/9 | 0/9 | 0/9 | 0/9 |
| Age, Continuous(Years) | SAD Cohort 1 | SAD Cohort 2 | SAD Cohort 3 | SAD Cohort 4 | SAD Cohort 5 | SAD Placebo Cohort | SAD Food Interaction Sub-study | MAD Cohort 1 | MAD Cohort 2 | MAD Cohort 3 | MAD Placebo Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 35.0 ± 12.5 | 34.2 ± 6.0 | 28.2 ± 7.0 | 40.5 ± 13.4 | 36.2 ± 8.9 | 33.3 ± 8.6 | 38.8 ± 12.3 | 34.6 ± 7.7 | 38.1 ± 9.9 | 37.1 ± 12.5 | 32.2 ± 11.1 | 35.2 ± 10.2 |
| Sex: Female, Male(Participants) | SAD Cohort 1 | SAD Cohort 2 | SAD Cohort 3 | SAD Cohort 4 | SAD Cohort 5 | SAD Placebo Cohort | SAD Food Interaction Sub-study | MAD Cohort 1 | MAD Cohort 2 | MAD Cohort 3 | MAD Placebo Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 3 | 3 | 4 | 2 | 7 | 3 | 2 | 3 | 3 | 4 | 36 |
| Male | 4 | 3 | 3 | 2 | 4 | 3 | 3 | 7 | 6 | 6 | 5 | 46 |
| Ethnicity (NIH/OMB)(Participants) | SAD Cohort 1 | SAD Cohort 2 | SAD Cohort 3 | SAD Cohort 4 | SAD Cohort 5 | SAD Placebo Cohort | SAD Food Interaction Sub-study | MAD Cohort 1 | MAD Cohort 2 | MAD Cohort 3 | MAD Placebo Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 3 |
| Not Hispanic or Latino | 6 | 6 | 5 | 6 | 6 | 10 | 5 | 8 | 9 | 9 | 9 | 79 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | SAD Cohort 1 | SAD Cohort 2 | SAD Cohort 3 | SAD Cohort 4 | SAD Cohort 5 | SAD Placebo Cohort | SAD Food Interaction Sub-study | MAD Cohort 1 | MAD Cohort 2 | MAD Cohort 3 | MAD Placebo Cohort | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| White | 5 | 6 | 5 | 6 | 5 | 10 | 5 | 8 | 8 | 8 | 9 | 75 |
| More than one race | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2024 to primary completion in Feb 2025, 8 months.
Results were first posted in May 2026, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: IRL757
Integrative Research Laboratories AB